By Finance Pulse in KeyInfo —

H.C. Wainwright Rates Nuvalent 'Buy' with $110 Target

H.C. Wainwright initiates coverage on Nuvalent (NUVL) with a 'Buy' rating and $110 price target, highlighting its potential in transforming lung cancer treatment.

An aesthetically pleasing image depicting a futuristic medical landscape, symbolizing the innovative
H.C. Wainwright Rates Nuvalent 'Buy' with $110 Target

H.C. Wainwright initiated Nuvalent (NUVL) with a Buy rating and $110 price target, citing potential in reshaping lung cancer treatment.

Source